Time course of synovial perfusion in nonremitting or nonresponding patients receiving methotrexate (MTX).
| Joint | DCE-MRI | Nonremission with MTX over Time | Nonresponse with MTX over Time | ||||
|---|---|---|---|---|---|---|---|
| E | SE | p | E | SE | p | ||
| MCP2 | ME | −15.6 | 6.7 | 0.02 | −15.5 | 7.0 | 0.03 |
| MV | −0.6 | 0.2 | 0.01 | −0.7 | 0.2 | 0.005 | |
| RE | −0.3 | 0.2 | 0.04 | −0.4 | 0.2 | 0.02 | |
| MCP3 | ME | −8.7 | 3.8 | 0.02 | −7.7 | 4.0 | 0.06 |
| MV | −0.4 | 0.2 | 0.02 | −0.4 | 0.2 | 0.02 | |
| RE | −0.3 | 0.1 | 0.009 | −0.3 | 0.1 | 0.01 | |
Dynamic contrast-enhanced MRI (DCE-MRI) was used to calculate maximum synovial enhancement (ME), maximum synovial volume (MV), and the rate of synovial enhancement (RE) in MCP2 and MCP3 of nonremitting or nonresponding rheumatoid arthritis patients (according to EULAR criteria) who received methotrexate therapy. Associations were according to linear mixed modeling. MRI: magnetic resonance imaging; E: estimate; SE: standard error; MCP: metacarpophalangeal joint; EULAR: European League Against Rheumatism.